Kornimate/medical-research-clean huggingface dataset:
perception of smell and taste during antibiotic treatment

Conditions: Infectious Disease

Summary: antibiotic use may be associated with effects on the perception of smell and taste. these effects are poorly known. the mechanisms can be very diverse, and the effect can be very variable depending on the type of antibiotic used, the dose, and the duration. the aim of this study is to analyze the perception of the taste and olfactory capacities of patients, during an antibiotic treatment.


Eligibility criteria:
inclusion criteria: * major patient * patient with bacterial infectious disease requiring antibiotic treatment. * having been informed about the study and not having opposed to participate exclusion criteria: * patient under legal protection * patient refusing to participate
relationship between symptoms, retinal morphology, and the nigrostriatal dopamine system in parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to examine if a correlation exists between findings from brain imaging studies of the status of the dopamine system in the brain using datscan and spect imaging, clinical symptoms of parkinson's disease, and changes in the structure of the retina as detected by optical coherence tomography (oct) in recently diagnosed and more advanced parkinson's disease patients.


Eligibility criteria:
inclusion criteria: 1. willing and able to give informed consent. 2. between the ages of 50-80 years old. 3. male or female with idiopathic pd who fulfill uk pd society brain bank criteria for diagnosis of parkinson's disease. 4. early stage subjects will need to have unified parkinson's disease rating scale (updrs) motor scores of \< 10, be within 3 years of diagnosis, and not requiring dopaminergic therapy 5. later stage subjects will need to have unified parkinson's disease rating scale motor scores of \> 20 and be \> 5 years from diagnosis 6. if female, one of the following three scenarios must apply: * at least two years post-menopausal * surgically sterile * negative urine pregnancy test, and following a reliable method of birth control (oral contraceptive, intrauterine device, contraceptive implant, barrier, or abstinence) for at least two months prior to entry, and agreeing both to follow a reliable method of birth control, and (if relevant) to desist from breast feeding during, and for two weeks following tracer administration. exclusion criteria: 1. abrupt onset of parkinsonism 2. 'other parkinson-like syndromes (e.g. progressive supranuclear palsy, multiple system atrophy) 3. any condition that would preclude successful completion of spect scanning 4. use of anti-coagulant therapy 5. any clinically significant eye disease that would complicate interpretation of oct data 6. use of any drugs that would alter or interfere with tracer binding for spect imaging studies (ex., cocaine, amphetamines, methylphenidate, ephedrine, phentermine, bupropion, fentanyl, selective serotonin reuptake inhibitors). 7. known sensitivity to the imaging agent or to lugol's solution or to potassium perchlorate. 8. history or presence of severe renal disease.
oxidative stress and vitamin d levels in autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: oxidative stress and vitamin d levels in autism spectrum disorders

introduction: the etiology of autism spectrum disorder (asd) is thought to be complex. increasing evidence in the literature shows that oxidative stress plays a role in the development and prognosis of autism. in our study, investigators aimed to investigate whether thiol disulfide balance, which is a new marker of oxidative stress, is different from that in normal children with autism spectrum disorder. methods a total of 68 children, 38 with autism spectrum disorder and 30 healthy controls, were included in the study. dynamic thiol balance, total oxidant status, total antioxidant status, ischemia-modified albumin, paraoxonase 1, and arylesterase activities were measured using colorimetric methods. routine biochemical parameters were obtained from their files and evaluated.

Eligibility criteria:
control group inclusion criteria: * healthy children who applied to the pediatric clinic for routine examination control group exclusion criteria: * children who have any chronic medical diseases or psychiatric disorders * children who have a family history of chronic medical diseases or psychiatric disorders autism spectrum disorder group inclusion criteria: * children with autism spectrum disorder (diagnosis based on the diagnostic and statistical manual of mental disorders, fifth edition, text revision (dsm-5-tr)) autism spectrum disorder group exclusion criteria: * children who have a family history of chronic medical diseases or psychiatric disorders

Keywords: oxidative stress vitamin d autism spectrum disorders
preventing malnutrition in children under two years of age approach

Conditions: Malnutrition

Summary: a study conducted by ifpri in haiti provided the first programmatic evidence, using a cluster randomized evaluation design, that preventing child undernutrition in children under two years of age (pm2a) through an integrated program providing food rations, bcc and preventive health and nutrition services is both feasible and highly effective. the study's principal aim was to compare a newly designed preventive approach with the traditional (recuperative) food assisted mchn program approach, and therefore included only two comparison groups: one group of communities that was randomly assigned to the preventive approach and another group assigned to the recuperative approach. for logistical and financial reasons, the study did not include a randomized control group receiving no intervention. the haiti study design was well-suited to achieve its main goal - i.e. to test whether the preventive approach was more effective than the recuperative approach at preventing child undernutrition - but it left a number of questions unanswered. the present study will address several of these questions, which will allow to further refine the pm2a approach, facilitate its replication in different contexts, and maximize its impact and cost-effectiveness in future programming. the study will be conducted in guatemala and burundi. the key research objectives are: 1. impact and cost effectiveness: assess the impact and cost effectiveness of pm2a on child nutritional status. 2. optimal composition and size of food rations in pm2a: assess the differential and absolute impact of varying the size and types of foods incorporated in the food ration of the pm2a. more specifically, assess the differential effect of different sizes of family food rations, and assess the impact of substituting the individual food ration with new micronutrient-rich products such as lipid-based nutrient supplements (lns) or micronutrient sprinkles. 3. optimal timing and duration of pm2a: assess the differential and absolute impact of varying the timing and duration of exposure to pm2a on child nutritional status.


Eligibility criteria:
inclusion criteria: * guatemala: pregnant mothers and subsequently their born children up to the age of 24 months; * burundi: cross-sectional study: children 0 to 42 of age. exclusion criteria: * none

Keywords: malnutrition; infant nutrition; fortified food linear growth cluster randomized controlled trials effectiveness impact evaluation studies burundi guatemala
pilot study of nicotine replacement for smoking cessation during pregnancy

Conditions: Tobacco Use Disorder

Summary: we plan to examine the feasibility, acceptability, preliminary quit rates, overall nicotine exposure and adverse effects of the nicotine inhaler for smoking cessation in pregnancy.

subjects in this pilot study are healthy pregnant women who wish to quit smoking. they will set a quit date and use the nicotine inhaler for 4 weeks. they will receive behavioral counseling in addition to the inhaler for 4 weeks.

Eligibility criteria:
inclusion criteria: * 13-26 weeks pregnant * smoking at least 5 cigarettes per day the preceding 7 days * motivated to quit smoking (at least 7 on a 10 pt. scale) * able to speak english * intend to carry pregnancy to term * stable residence exclusion criteria: * current drug or alcohol abuse or dependence (other than methadone maintenance * twins or multiple gestation * unstable psychiatric disorder * unstable medical problems * known congenital abnormality * high risk pregnancy

Keywords: smoking cessation during pregnancy nicotrol inhaler
carolina alcohol and drug resources

Conditions: HIV

Summary: substance abuse is highly prevalent among individuals with hiv and associated with negative outcomes including poorer medication adherence and hiv risk behavior. the primary aim of this project is to address substance abuse among individuals with or at high-risk for hiv by enhancing and expanding the substance abuse services provided in the formerly substance abuse and mental health services administration (samhsa) funded carolinas alcohol and drug expansion team (cadet) program, which offered comprehensive substance abuse care for individuals with hiv living primarily in the durham nc area. services will be enhanced by adding peer outreach and navigation services to improve treatment engagement and participation and expanded to replicate the enhanced cadet service model in charlotte nc. the target population for this project is minority individuals, primarily african-americans, with hiv or at high-risk for hiv with a particular focus on minority men who have sex with men (msm)s. the program will provide up to 18 months of comprehensive services for approximately 315 individuals and will include: 1) peer outreach to facilitate and enhance treatment engagement 2) individual and group substance abuse treatment using evidence-based models 3) ongoing recovery groups for individuals who have completed the intensive substance abuse treatment phase and 4) linkage to needed services such as case management, psychiatric care, and hiv/hepatitis medical care. we will also target hiv and hepatitis c testing and treatment services for minority msm of unknown hiv status to increase access and utilization of substance use services and identify hiv and hepatitis status. the study evaluation will involve analysis of participant survey data gathered at baseline, 6, 12, 18 months of study participation to determine the effect of the comprehensive substance abuse care services on outcomes for individuals with hiv including substance use, mental health, hiv treatment adherence, hiv risk behavior, and access and utilization of hiv services. the study will also determine the effect of the comprehensive substance use program on substance abuse, mental health, and risk behavior outcomes for minority msm who are not hiv-positive.


Eligibility criteria:
inclusion criteria: * hiv-positive or minority msm * substance abuse * 18 or over exclusion criteria: * under 18 * cognitive impairment that would preclude participation in substance abuse treatment
patients with acute hip fractures will receive either the peng block or no block respectively.

Conditions: Hip Fractures

Summary: hip fracture pain is often severe and traditionally managed by systemic opioids which have increased risk of side effects in frail elderly patients. inadequately controlled pain may lead to delirium which increases mortality and morbidity. the overall aim of this rct is to investigate the potential for improved pain relief accomplished by the addition of the peng block to current standard practice of pre-operative analgesia (systemic morphine), compared to the control group, which involves no block (operator will still go through the motion as if performing a block) plus standard pre-operative analgesia. the investigator hypothesize that the addition of a single shot peng block at the side of hip fracture in addition to traditional systemic morphine provides good preoperative pain relief on movement and reduces the need for breakthrough opioid requirements. the investigator hypothesize that the interventional group dynamic pain score assessed at 30 minutes after the block compared to control group dynamic pain score at 30 minutes after the "block" will be at least a 3 point difference between the 2 groups .

specific aim1: to determine difference in pain scores on movement (dynamic pain scores) in patients who receive the peng block in the intervention group compared to no block in the control group at 30 minutes after performance of the block. specific aim2: to determine if there is any difference in pain at rest between the intervention group and the control group, and if so, the magnitude of the difference in pain scores.

Eligibility criteria:
inclusion criteria: 1. age 60 years old and above 2. provided consent for the study 3. patients with solitary hip fracture (no other fracture) - intracapsular neck of femur fracture, intertrochanteric fracture 4. either awaiting hip fracture surgery or no plans for hip fracture surgery within the next 24 hours exclusion criteria: 1. patients with cognitive impairment or inability to give consent, or refusal to give consent 2. multiple fracture cases 3. peri-prosthetic fractures and revisions 4. subclinical vertebral fractures 5. hip fractures due to major accidents such as road traffic accidents, fall from height or more than 2 meters 6. multiple trauma 7. pathological fractures secondary to metastases 8. patients with contraindications to block performance * coagulopathy as demonstrated by pt/ptt/inr * on antiplatelets or anticoagulation * infection/ compromised skin integrity at site of block performance * allergy to local anaesthetics and opioids

Keywords: hip fractures, elderly, pain
kerastat skin therapy in treating radiation dermatitis in patients with newly diagnosed stage 0-iiia breast cancer

Conditions: Ductal Breast Carcinoma in Situ; Skin Reactions Secondary to Radiation Therapy; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer

Summary: this pilot clinical trial studies kerastat skin therapy in treating radiation dermatitis in patients with newly diagnosed stage 0-iiia breast cancer. radiation dermatitis is an itchy, painful skin rash that can occur following treatment with radiation. kerastat skin therapy may be a better treatment for radiation dermatitis.

primary objectives: i. to obtain a preliminary estimate the incidence of early adverse skin reaction (easr) during radiation therapy (rt) and up to two months post rt after the application of the cosmetic cream kerastat skin therapy during rt in breast cancer patients in a pilot study. secondary objectives: i. to associate personal characteristics (e.g., race/ethnicity, age, hormone therapy, smoking status, comorbidities, breast size) and treatment characteristics (e.g., rt dose) to incidence of easr at any time point. outline: patients apply kerastat skin therapy topically twice daily (bid) during radiation therapy. after completion of study treatment, patients are followed up at 1 and 2 months.

Eligibility criteria:
inclusion criteria: * newly diagnosed with breast carcinoma, stage 0-iiia (including ductal carcinoma in situ \[dcis\]) * status post-lumpectomy, -quadrantectomy, or -mastectomy * plan to receive adjuvant radiation to the whole breast or chest wall +/- regional lymph nodes * total dose \>= 40gy * dose per fraction \>= 1.8 use of 2-dimensional (2d), 3-dimensional (3d) conformal, or intensity-modulated radiation therapy (imrt) treatment techniques allowed; skin sparing imrt patients excluded; a daily fraction of 2.7 gy to the whole breast is suggested for hypofractionated regimens * concurrent and sequential boost techniques are allowed for both standard and hypofractionated regimens * adjuvant hormonal therapy will be allowed prior to, during and/or after rt at the discretion of a medical oncologist * targeted therapies such as herceptin will be allowed prior to, during, and/or after rt at the discretion of the medical oncologist * patients who are able and willing to sign protocol consent form exclusion criteria: * prior radiation to the involved breast or chest wall * concurrent chemotherapy; (patients may receive chemotherapy prior to radiation or following radiation at the treating physician's discretion) * patients who underwent breast reconstruction following mastectomy (placement of tissue expanders and implants are not allowed) * patients undergoing partial breast irradiation * patients who have undergone mammosite® or any other form of brachytherapy * patients may not be concurrently enrolled in a protocol that involves treatment of the skin ie: applying lotions /moisturizers; protocols that do not involve treatment of the skin are allowed * patients who are pregnant or breastfeeding
diphenylcyclopropenone (dpcp) as a depigmenting therapy in extensive vitiligo

Conditions: Vitiligo

Summary: the aim of the present work is to evaluate the efficacy and safety of diphenylcyclopropenone (dpcp) as a depigmenting therapy in extensive vitiligo.

depigmentation protocol: (aghaei et al, 2005) * substance used: dpcp (fluka, sigma-aldrich, saint louis, mo (missouri), usa) 98% pure powder. * dpcp will be dissolved in acetone to obtain 2% solution. * dpcp solutions will be kept in dark colored bottles at 4ºc (degree celsius). * sequential dilution by acetone to yield 1%, 0.5%, 0.1%, 0.01%, 0.05 and 0.001%. * sensitization by dpcp concentration 2% will be applied to an area 5×5 cm on the forearm * two weeks following sensitization, treatment will be started by weekly applications of incremental concentrations of dpcp (between 0.001% and 2%) adjusted according to the patient's reactivity to the contact allergen. the aim will be to maintain mild contact eczema and itch for about 48 hours after application. patients will be instructed to avoid direct sun exposure of the treated area and not to wash it for 48 hours after each application. patient follow-up: patients will come for sensitization at week 0, then after 2 weeks to look for the allergic response, then weekly to reach the effective dose of dpcp. after reaching the effective dose, patients will come weekly to apply dpcp and to look for depigmentation, record possible side effects for 12 consecutive weeks. assessment of depigmentation: for each treated area, response will be assessed as follows (van geel et al., 2015): * digital clinical pictures will be used to evaluate the capacity to induce depigmentation and to assess the percentage of depigmentation per test area. * treatment results will be subsequently classified according to a grading system from 0 to 6 (0 = no effect, 1 = \<25%; 2 = 25-49%; 3= 50-47%; 4= 50-74%; 5=90-99%; 6=100%), corresponding to the grade of depigmentation. reporting any side effects: such as pain, erythema, blisters, erosions, hyperpigmentation, scarring, appearance of depigmentation in distant sites and/or systemic manifestations (venkatesh et al,2018) .

Eligibility criteria:
inclusion criteria: 1. adult patients of both genders ≥ 18 years. 2. vitiligo universalis patients with cosmetically unacceptable residual pigmentation. 3. extensive vitiligo vulgaris ≥ 50% body surface area (bsa) involvement with areas recalcitrant to repigmentation on exposed skin with consequent psychological impairment. exclusion criteria: 1. children. 2. early, localized, segmental or any vitiligo case responsive to repigmentation treatment. 3. pregnant and lactating females. 4. patients with history of any malignancy. 5. patients with active infectious or inflammatory dermatoses. 6. patients with a history of hypertrophic scars or keloids. 7. patients suffering from cardiac, hepatic or renal disorders.
aperio® hybrid thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke

Conditions: Acute Stroke

Summary: this is a prospective, multicenter, single-arm, open-label, national post-market clinical follow-up study to collect comprehensive information on technical and clinical success and safety of the use of aperio® hybrid(17/21) thrombectomy device in clinical practice. aperio® hybrid(17/21) thrombectomy device will be used within its approved indication.

german aperio® hybrid post- market clinical follow-up study aperio® hybrid pmcf study- thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke study type: prospective, multicenter, single-armed, open-label participants: 8 participating centers in germany pi: dr. christian mathys, evangelisches krankenhaus oldenburg, germany estimated enrolment: 190 patients treated with aperio® hybrid(17/21) thrombectomy device as a result of an acute stroke follow up: 3 months estimated final assessment: mid to end of 2023

Eligibility criteria:
inclusion criteria: - all patients treated with aperio® hybrid and/or aperio® hybrid(17/21) thrombectomy device as a result of an acute stroke. exclusion criteria: * patient age \< 18 years * pre stroke mrs ≥ 3
comparıson of the effects of perıcapsulary nerve group block (peng block) and lumbar erector spına plan block (lesp block) on postoperatıve opıoıd consumptıon

Conditions: Pengblock; over65years; Lumbar Erector Spinae Plane Block; Hipfracture

Summary: the aim is to demonstrate that lumbar esp block provides more effective postoperative analgesia than peng block in geriatric patients with hip fractures, and reduces postoperative opioid consumption more than peng block


Eligibility criteria:
inclusion criteria: * patients with hip fractures * over 65 years old exclusion criteria: * long-term surgery * patients who do not want regional anesthesia * bleeding disorder disease * wound in the operation area
analgetics vs analgetics and antibiotics for pediatric clinical and sonographic orchitis or epididymitis

Conditions: Epididymitis Orchitis

Summary: some children are admitted to pediatric emergency department due to epididymitis or orchitis. some of them are treated by analgetics only whie some are treated by analgetics with antibiotics. the study will compare clinical presentation between groups and will compare pediatric urologic outpatient clinic follow up findings.

some children are admitted to pediatric emergency department due to epididymitis or orchitis. some of them are treated by analgetics only whie some are treated by analgetics with antibiotics. the study will compare clinical presentation between groups and will compare pediatric urologic outpatient clinic follow up findings.

Eligibility criteria:
inclusion criteria: * all children admitted to pediatric emergency department due to epididymitis or orchitis exclusion criteria: * no sonographic or laboratory exam * antibiotic treatment before diagnosis * no outpatient follow-up * known urologic congenital malformations * admission to inpatient department or emergency surgery
line probe assay evaluation study

Conditions: Multidrug-Resistant Tuberculosis; Isoniazid Resistant Pulmonary Tuberculosis; Rifampicin Resistant Tuberculosis; Pulmonary Tuberculoses

Summary: this is a multi-center, blinded study to determine the performance of the yd diagnostic corporation (yd) reba mtb-mdr® and hain genotype mtbdrplus v2 kit in a total of 600 clinical isolates and 900 residual sputum samples from patients with symptoms of pulmonary tb (ptb) and at risk of drug resistance. all testing was done on stored, de-identified leftover samples. the study involved three world health organization (who) supranational reference laboratories with well-characterized strain collections and access to sputum samples with significant rates of drug resistance.


Eligibility criteria:
inclusion criteria: * age over 18 years * informed consent * patients evaluated for pulmonary tb exclusion criteria: -